Recent developments in the management of haemophagocytic lymphohistiocytosis

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 9, 2001, Pages 1437-1448

  Imashuku, S ^a   Teramura, T ^a   Morimoto, A ^a   Hibi, S ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Acylovir; Antithrombin III; Antithymocyte globulin; Corticosteroids; Cyclosporin A; Cytokine; Etoposide; Gancyclovir; Haemophagocytic lymphohistiocytosis; Intravenous immunoglobulin; Methotrexate

Indexed keywords

ACICLOVIR; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; DEXAMETHASONE 21 PALMITATE; DEXAMETHASONE DERIVATIVE; ETOPOSIDE; FERRITIN; FRESH FROZEN PLASMA; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; LIMETHASONE; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PERFORIN; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE;

APOPTOSIS; BLOOD CLOTTING DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE MARKER; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDICATION; EPSTEIN BARR VIRUS; FAMILIAL DISEASE; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HIGH RISK PATIENT; HISTIOCYTOSIS; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; NEUTROPENIA; PARAMETER; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SURVIVAL; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ANIMALS; HISTIOCYTOSIS, NON-LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0034839253     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.9.1437     Document Type: Review

References (136)

1. Diagnostic guidelines for hemophagocytic lymphohistiocytosis
2. Differential diagnosis of hemophagocytic syndrome: Underlying disorders and selection of the most effective treatment
3. Advances in the management of hemophagocytic lymphohistiocytosis
4. Hemophagocytic syndrome (HPS) in children and adults
5. Autoimmune-associated hemophagocytic syndrome
6. Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance
7. Familial hemophagocytic lymphohistiocytosis
8. Hemophagocytic lymphohistiocytosis: Diagnosis, treatment, and prognostic factors. Report of 122 children from the international registry
9. X-linked lymphoproliferative disease: Twenty-five years after the discovery
10. Treatment of Chediak-Higashi syndrome by allogeneic bone marrow transplantation: Report of 10 cases
11. Protein truncation test of LYST reveals heterogeneous mutations in patients with Chediak-Higashi syndrome
12. Partial albinism with immunodeficiency (Girscelli syndrome)
13. Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS)
14. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives
15. Severe chronic Epstein-Barr virus infection with natural killer cell defect
16. Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis
17. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping
18. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity
19. Further evidence for genetic heterogeneity in familial hemophagocytic lymphohistiocytosis
20. Perforin gene defects in familial hemophagocytic lymphohistiocytosis
21. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene
22. The X-linked lymphoproliferative disease gene product SAP regulates signals induced through the co-receptor SLAM
23. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome
24. Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis: Reversal with VP16 and indomethacin
25. Interleukin-2 induced activation of coagulation and fibrinolysis: Resemblance to the changes seen during experimental endotoxaemia
26. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes
27. Coagulation and fibrinolytic abnormalities in the mononuclear phagocyte system proliferative disorders-with special reference to hemophagocytic histiocytic syndrome
28. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis
29. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis
30. Central nervous system involvement in the erythrophagocytic disorders of infancy: The role of cerebrospinal fluid neopterins in their differential diagnosis and clinical management
31. High serum ferritin level as a marker of malignant histiocytosis and virus-associated hemophagocytic syndrome
32. Serum and urine beta-2-microglobulin in hemophagocytic syndrome
33. Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia
34. Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients
35. Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes
36. Clinicopathological findings of virus-associated hemophagocytic syndrome in bone marrow association with Epstein-Barr virus and apoptosis
37. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay
38. Immunologic dysregulation in a patient with familial hemophagocytic lymphohistiocytosis
39. Soluble interleukin-2 receptor: A useful prognostic factor for patients with hemophagocytic lymphohistiocytosis
40. Haemophagocytic lymphohistiocytosis, inferferon-gamma-naemia and Epstein-Barr virus involvement
41. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis
42. Involvement of interferon-γ and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults
43. Oversecretion of IL-18 in hemophagocytic lymphohistiocytosis: A novel marker of disease activity
44. Development of a corticosteroid incorporated in lipid microspheres (liposteroid)
45. Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis
46. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy
47. Liposteroid (dexamethasone palmitate) therapy for West syndrome: A comparative study with ACTH therapy
48. High-dose gamma globulin therapy in the reactive haemophagocytic syndrome
49. Intravenous immunoglobulin in virus associated haemophagocytic syndrome
50. Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome
51. Steroid and gamma globulin therapy against virus-associated hemophagocytic syndrome
52. Virus-associated hemophagocytic syndrome due to rubella virus in an adult
53. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis
54. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis
55. Deleterious effects of high dose gamma-globulin therapy on patients with hemophagocytic syndrome
56. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vitro
57. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations
58. Immunologically active protein in intravenous immunoglobulin
59. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis
60. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin
61. Brain SPECT imaging and treatment with IVIG in acute post-infectious cerebellar ataxia: Case report
62. The mechanisms of action of cyclosporin A and FK506
63. Cyclosporine: Update on pharmacology, analytical techniques and therapeutic monitoring
64. Haemophagocytic syndrome treated with cyclosporin A: T cell disorder?
65. The use of cyclosporin-A in the treatment of virus-associated hemophagocytic syndrome in adults
66. Treatment of hemophagocytic lymphohistiocytosis with cyclosporin A and steroids in a boy with lysinuric protein intolerance
67. Neutropenia associated with T-cell large granular lymphocyte leukemia: Long-term response to cyclosporine therapy despite persistence of abnormal cells
68. Chronic T-cell lymphocytosis with neutropenia. Its association with Epstein-Barr virus infection
69. Severe neutropenia in a patient with large granular lymphocytosis: Prolonged successful control with cyclosporin A
70. Treatment of chronic neutropenia associated with large granular lymphocytosis with cyclosporine A and filgrastim
71. Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH)
72. Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A
73. HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis
74. Reversible posterior leukoencephalopathy in a patient receiving cyclosporin therapy
75. Acute leukoencephalopathy during cyclosporin A therapy in a patient with nephrotic syndrome
76. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A
77. Dramatic efficacy of antithymocyte globulins in childhood EBV-associated haemophagocytic syndrome
78. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of VP16-213, steroids, intrathecal methotrexate and cranial irradiation
79. Methotrexate use in rheumatoid arthritis. A clinician's perspective
80. Methotrexate therapy to alleviate anaemia in a patient with large granular lymphocytosis
81. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213
82. Immunosuppression: Preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistiocytosis (FHL)
83. The accelerated phase of Chediak-Higashi syndrome
84. Etoposide (VP16) inhibits Epstein-Barr virus determined nuclear antigen (EBNA) synthesis
85. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: Disease spectrum, pathogenesis, and management
86. Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis
87. Neuropathology of familial erythrophagocytic lymphohistiocytosis: Six cases and review of the literature
88. Familial hemophagocytic lymphohistiocytosis: Improved neurodevelopmental outcome after bone marrow transplantation
89. MRI in acute disseminated encephalomyelitis
90. Acyclovir inhibition of Epstein-Barr virus replication
91. Acyclovir for treatment of infectious mononucleosis: A meta-analysis
92. Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study
93. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis
94. Management of Epstein-Barr virus infections
95. Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation
96. A case of Epstein-Barr virus associated hemophagocytic syndrome treated with vidarabine
97. The anti-inflammatory properties of antithrombin III: New therapeutic implications
98. Antithrombin III in patients with severe sepsis: A pharmacokinetic study
99. Therapeutic rationale for antithrombin III in sepsis
100. Severe neutropenia in T-large granular lymphocyte leukemia corrected by intensive immunosuppression
101. G-CSF enhanced granulocyte production in a child with severe neutropenia in the setting of fatal virus associated hemophagocytic syndrome
102. Successful treatment of virus-associated haemophagocytic syndrome in adults by cyclosporin A supported by granulocyte colony-stimulating factor
103. Enhancement of monocytopoiesis by granulocyte colony-stimulating factor: Evidence for secondary cytokine effects in vivo
104. Risks of rhG-CSF treatment in drug induced agranulocytosis
105. Granulocyte colony-stimulating factor exacerbates acute lung injury induced by intratracheal endotoxin in guinea pigs
106. The effect of protease inhibitors in shock
107. Nafamostat mesilate treatment during open heart operation in immune thrombocytopenic purpura
108. Antioxidant action of FOY in an experimental model of hypergeneration of oxygen free radicals
109. Study of effect of ulinastatin for pulmonary aspergillosis model mice
110. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
111. Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease
112. Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: Study of 47 South African cases
113. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: Prior infection by EBV and other agents
114. B-cell lymphoma-associated hemophagocytic syndrome
115. Correction of Duncan's syndrome by allogeneic bone marrow transplantation
116. Bone marrow transplantation during fulminant EBV-infection in Duncan's syndrome
117. Brief report: Correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells
118. Allogeneic bone marrow transplantation in hemophagocytic lymphohistiocytosis in Sweden
119. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation
120. Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: A single-centre experience of 12 patients
121. Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan
122. Blood stem cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation
123. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection
124. Hemophagocytic syndrome in relation to NK/T neoplasmas - Clinical features of NK-cell type hemophagocytic lymphohistiocytosis (NK-HLH)
125. Adenovirus-related hemophagocytic syndrome after bone marrow transplantation
126. Virus-associated hemophagocytic syndrome following bone marrow transplantation
127. Graft failure due to hemophagocytic syndrome after autologous peripheral blood stem cell transplantation
128. Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis
129. Prolonged resolution of hemophagocytic lymphohistiocytosis following myeloablasive chemotherapy and subsequent autologous peripheral blood stem cell transplantation
130. Successful engraftment of haploidentical stem cell transplant for familial haemophagocytic lymphohistiocytosis using both bone marrow and peripheral blood stem cells
131. Unrelated 5/6-locus matched umbilical cord blood transplantation in a 23-month-old child with hemophagocytic lymphohistiocytosis
132. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically non-identical donors
133. Hemophagocytic lymphohistiocytosis in infancy and childhood
134. Secondary acute myelogenous leukemia following safe exposure to etoposide
135. Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome
136. Secondary acute myeloid leukemia after successful immunochemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis